By Anjali Rao Koppala (Reuters) - Sunesis Pharmaceuticals Inc said its experimental cancer drug did not meet the main goal in a late-stage trial, sending the company's shares plunging 77 percent to their lowest in more than two years. The stock's slump fall wiped out over $300 million of the company's market value. Sunesis on Monday said the overall survival rate of patients given the drug, vosaroxin, was not statistically significant compared to patients who were given a placebo. The company said it plans to meet the U.S. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment